As previously reported, Leerink analyst David Larsen upgraded Cerner to Outperform from Market Perform, with a $70 price target, as he believes its base continues to deliver steady growth due partly to consistent hospital M&A activity, the deal with Lumeris positions the company to be able to ramp its population health solution to an "Evolent" type of asset, Cerner's revenue cycle product continues to improve and 88% of revenue is recurring or highly visible. The analyst also likes how the company won the VA deal, which should add about $10B of bookings over about 10 years, and expects margins to return to expansion in 2019.